SciSparc Ltd. SPRC 深 滬
已收盤 04-02 16:00:00 美东时间
3.54
-0.120
-3.28%
華盛通- 最 高3.67
- 今 開3.67
- 成交量 1.05万股
- 最 低 3.37
- 昨 收 3.66
- 總市值 200.19万
- 52周最高 94.50
- 市盈率 靜 --
- 換手率 1.85%
- 52周最低 3.37
- 委 比 0.00%
- 總股本 56.55万
- 歷史最高 34791.12
- 量 比 0.83
- 振 幅 8.20%
- 歷史最低 3.37
- 每 手 1
- 風險率 21.92%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers iSpecimen (NASDAQ:ISPC) shares moved upwards by 70.7% to $0.38 during ...
03-13 05:05
Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
Clearmind Medicine Inc. has published an international patent application for a novel combination therapy using MEAI and Palmitoylethanolamide (PEA) to treat obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). The therapy targets a growing market valued at $37 billion in 2025 and expected to reach $226 billion by 2035. MEAI-PEA may offer a safer, non-hallucinogenic alternative to GLP-1 agonists, addressing global health ...
03-10 12:59
SciSparc Announces 1-for-9 Reverse Share Split
SciSparc Ltd. announced a 1-for-9 reverse share split effective March 4, 2026, reducing outstanding shares to approximately 565,000. No fractional shares will be issued; adjustments will be made to exercise prices and shares under options/warrants. SciSparc, through NeuroThera Labs, focuses on cannabinoid-based pharmaceuticals for treatments like Tourette's syndrome and Alzheimer's. The press release includes forward-looking statements subject to...
03-02 13:00
SciSparc Amends $10 Million Note Deal, Issues $2 Million Initial Convertible Note
SciSparc Ltd. ( ($SPRC) ) has shared an announcement. On February 12, 2026, Sci...
02-18 05:29
SciSparc Shareholders Approve February Governance Agenda
SciSparc Ltd. ( ($SPRC) ) has shared an update. Shareholders approved all propo...
02-05 05:30
CORRECTION: SciSparc Acquires MUSE IP Portfolio From Xylo in Equity-Based Asset Deal; SciSparc Issued To Xylo An Amount Of Ordinary Shares Of The Company, Which Represents 19.99% Of The Issued And Outstanding Share Capital Of SciSparc
SciSparc intends to target the global multi- billion dollar GERD device marketTEL AVIV, Israel, Jan. 26, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a company engaged in clinical-stage
01-26 21:19
SciSparc Acquires IP Portfolio Of Patents, Trademarks, IP Rights For Endoscopic Systems, Medical Cameras; Financial Terms Not Disclosed
SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a company engaged in clinical-stage pharmaceutical developments through its majority-owned subsidiary NeuroThera Labs Inc., announced today the closing of the
01-26 21:17
SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization
<p>SciSparc announced the acquisition of intellectual property from Xylo Technologies, including the MUSE™ system, designed for treating GERD. Targeting the global GERD device market valued at $2.5 billion in 2024, SciSparc plans to replicate Xylo's successful licensing model in high-growth regions to accelerate commercialization and revenue.</p>
01-26 13:13
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Greenwich LifeSciences (NASDAQ:GLSI) shares rose 48.6% to $33.13 durin...
01-22 20:05
SciSparc Moves Into Endoscopy With Strategic Patent Deal
SciSparc shares fall after the company agrees to acquire endoscopy-related patents as it pushes into medical devices.
01-14 02:39
